Loading
A phase 3 trial of Sacituzumab tirumotecan, Bevacizumab in ovarian cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) is a phase 3 interventional study registered as NCT07318558 by Merck Sharp & Dohme LLC, with 900 participants planned, started 2026-02-16 and due to reach its primary completion in 2033-02-25. Interventions recorded: Sacituzumab tirumotecan, Bevacizumab, Rescue Medications. Conditions listed: Ovarian Neoplasms, Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Sacituzumab tirumotecan, Bevacizumab, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Bevacizumab, Anti-angiogenic therapy, Topoisomerase-I inhibitors (and ADC payloads).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).